Tharp MD, et al. - Researchers aimed to quantitatively synthesize the known benefits and harms of omalizumab in the real-world clinical management of chronic idiopathic urticaria (CIU) (also known as chronic spontaneous urticaria) regarding urticaria activity, treatment response, and adverse events. This meta-analysis of 67 published reports on real-world effectiveness revealed omalizumab therapy to be effective in inducing an average 25.6-point improvement in weekly Urticaria Activity Score (vs a 14.9 to 22.1 point improvement reported in clinical trials), a 4.7 point improvement in Urticaria Activity Score, a complete response rate of 72.2%, and a partial response rate of 17.8% with an average adverse event rate of 4.0% (vs 2.9%-8.0% reported in clinical trials). Hence in the real-world treatment of chronic idiopathic urticaria, omalizumab had benefits and safety profile meeting or exceeding the results obtained from clinical trials.